Latka logo

Founder Interview

How Enzyme Reached 21 Customers Helping Life Science Companies Navigate FDA Compliance (Interview with CEO Jared Seehafer)

Interview Date
December 3, 2018
Interviewee
Jared SeehaferCo-Founder and CEO
Watch
Watch the full interview

Company Metrics at Interview Time

Customers (2018)

21

Team Size (2018)

8

Total Funding Raised (2018)

A couple million dollars

Investor

Y Combinator

Historical Snapshot

These numbers were reported by Jared Seehafer during the interview recorded in December 2018 and are a historical snapshot, not current figures. See Enzyme’s current numbers.

Key Takeaways

  • 01Enzyme launched in Q1 2018 after operating in quasi-stealth mode during 2017
  • 0221 companies were using the platform in production as of December 2018, from garage startups to enterprise organizations
  • 03Pricing ran from 5 figures to 7 figures a year, depending on company size and the number of products a customer was doing
  • 04Enzyme went through Y Combinator and subsequently raised a seed round from VCs
  • 05Enzyme had raised a couple million dollars in total, all on SAFEs, and had not yet raised a priced round
  • 06The team consisted of 8 people split between San Francisco and remote locations
  • 07Jared said Enzyme didn't really see churn: because regulatory compliance runs for the life of a company, churn for Enzyme was a customer getting bought or acquired
  • 08A lot of the growth to date had come from word-of-mouth among entrepreneurs in the life science space
  • 09Jared was 33 years old at the time of the interview
  • 10Enzyme was close to but not yet at cash flow positive at the time of the interview

Company Metrics at Time of Interview

MetricValueSource
Customers (2018)21Founder interview, Dec 2018
Team Size (2018)8Founder interview, Dec 2018
Total Funding Raised, all on SAFEs (2018)A couple million dollarsFounder interview, Dec 2018
Annual Contract Value (garage startup tier) (2018)$50,000Founder interview, Dec 2018
Annual Contract Range (2018)5-figure to 7-figure per yearFounder interview, Dec 2018

Growth Breakdown

Customers

By December 2018, 21 companies were using the Enzyme platform in production, from garage startups and product teams to large enterprise organizations. The company launched commercially in Q1 2018 after a period of quasi-stealth development in 2017.

Team

Jared built a team of 8 people by the time of the interview, mixing software developers and regulatory domain experts. The team operated across San Francisco and remote locations, a deliberate choice given the high cost of living in the Bay Area.

Funding

Jared said Enzyme had raised a couple million dollars in total. It did a small friends-and-family round when he was just getting started, then went through Y Combinator, then raised a seed round from various VCs active around that YC cohort. All of it was on SAFEs; the company had not raised a priced round.

Profitability

At the time of the interview, Enzyme was close to but not yet at cash flow positive. Jared indicated the company was about to increase burn by hiring an enterprise sales force to move upmarket toward larger organizations.

Growth Strategy

Word-of-Mouth Within the Life Science Community

Jared said Enzyme got a lot of its growth just from word-of-mouth. Life science entrepreneurs tend to know each other and share solutions to common problems, which allowed Enzyme's name to spread organically through the community over its first year.

Y Combinator and the Seed Round

Enzyme went through Y Combinator, then raised its seed round from various VCs active around that YC cohort right after the program. Asked whether YC teaches companies to drive to cash-flow positive before a priced round, Jared said "not really": as he saw it, YC asks what is best for the overall business, and getting to cash-flow positive only to fall flat on your face is "not very helpful for anybody."

Founder Domain Expertise as a Sales Tool

Jared spent his career as a biomedical engineer, and the host introduced him as a twelve-year veteran of the medical device and biopharma industries. His first customer came from a chance conversation at a Jason Calacanis launch event where his deep knowledge of the regulatory process prompted the CEO of a life science company to request a demo on the spot.

Pricing Tied to Customer Size and Value Delivered

Enzyme structured its pricing to reflect the cost savings it delivered relative to hiring human regulatory experts. Smaller companies that would otherwise spend six figures on labor could access the platform at a lower cost, making the value proposition clear and the decision achievable.

Targeting Ongoing Compliance, Not Just One-Time Approvals

Rather than positioning as a point-in-time approval tool, Enzyme emphasized that regulatory compliance is a continuous obligation for life science companies throughout the life of the business. This framing supported long-term customer relationships and made churn structurally unlikely.

Best Quotes

“So we've got 21 companies that are using the platform in production of various sizes, everything from sort of product teams to the large organizations, enterprise organizations to, like I said, kind of a garage startup.”
“So we were in sort of quasi stealth, though I hate the term in 2017, launched the company earlier this year in 2018, Q1.”
“We went through Y Combinator Accelerator, did a small friends and family round, kind of just when I was just getting started. Then went through YC and then raised a seed stage round of capital, you know, through various VCs that are kind of in that, at that cohort right after YC.”
“So we've got eight people on staff here and we've various kind of mix of developers and sort of regulatory experts.”
“Well, so for the nature of our business is such that we don't really see churn. Churn for us is a customer getting bought or acquired.”
“I'm trying to scratch my own itch. I'm trying to solve problems and create the kind of software that I wish I had had as someone building lifesaving technology.”
“We are big Slack fans. I I think Slack's one of these things that gets a bad rap, but I think you tune it very well. It's been essential to us in kinda keeping, you know, keeping a quasi remote org.”
“I've had this idea percolating in my mind for ever since I started my career. And I always was thinking, why isn't anyone doing this? Why isn't anyone doing this? Why isn't anyone doing this? And I got... Eventually I just got fed up enough that I was... I'm gonna go do it.”

What Happened Next

This interview captured Enzyme at an early stage in December 2018, just months after its commercial launch in Q1 of that year. At the time, the company had 21 customers, a team of 8, and was "not quite, but close" to cash-flow positive, with plans to hire an enterprise sales force that would drive up burn. Visit the Enzyme company profile on GetLatka for additional context on the company's trajectory.

View Enzyme’s current profile and metrics

Run a software or AI company? Get interviewed by Nathan Latka and tell the story behind your numbers.

Full Transcript

Introduction and What Enzyme Does

Nathan Latka

00:00Hello, everyone. My guest today is Jared Seehafer. He is the CEO and co founder of Enzyme, a software company that automates life science, regulatory approval and compliance. He's a twelve year veteran of the medical device and biopharma industries having worked or consulted at organizations ranging Amgen, Abbott and Medtronic to seed-stage startups. Jared, are you ready to take us to the top?

Jared Seehafer

00:20Let's do it.

Nathan Latka

00:20All right, complex space here. Help us understand what you do and how you make money.

Jared Seehafer

00:24Sure thing. So if you are a company making a life science technology, this is gonna be drug, medical device, diagnostic, something like an MRI, a pill, anything that is used in the practice of medicine besides a doctor or a nurse kind of rendering professional judgment. There's a complex regulatory pathway you have to go through and it's different for every country. In The United States, that's the FDA. Most people are familiar with that, but every every geography

00:52has its own version of the FDA. On the market, you have to go through a number of complex regulatory processes. These are steps you have to do where you essentially present a case to the government as to why your product is, quote, safe and effective. It both is safe to the to user for its use, and it's also gonna do what you say it's going to do. So you can't sell snake oil. And that's... It's a

01:15it's a complex process. And if you're a large company, you generally just hire an army people who are expert in doing this process. It's a whole professional organization with its own, you know, its own career path.

Nathan Latka

01:30Uh-huh.

Jared Seehafer

01:31But if you're a smaller organization, that can be very challenging because it's expensive. And so if you're a little startup, you've got this great new product, great new idea. You wanna see it. You're you're talking of spending hundreds of thousands of dollars in addition to the development cost of your product, for your product to ever see the light of day. And so what we're trying to do at Enzyme is to use software to radically simplify the

01:54amount of human labor that goes into making all of this documentation that the government needs to say yes or no.

Pricing Model and Contract Structure

Nathan Latka

02:01Okay. And pricing models, is it pure play SaaS or?

Jared Seehafer

02:05Exactly. Yeah. So we we have a... They're essentially, an ongoing SaaS relationship with our customers, sometimes with some add on services depending what they need. Do they need a human voice in front of FDA, that kind of thing? But it's generally a SaaS product. Yep.

Annual Contract Value and Customer Tiers

Nathan Latka

02:19Okay. And help me understand, mean, generally speaking, are we talking people paying you a grand a month or $10 a month or 1,000,000 a month? What scale are you playing at?

Jared Seehafer

02:26Yeah. So it's anywhere depending on company size from a 5 figure to a 7 figure a year type of situation. And we we try to bias it based on company size, number of products they're doing, etcetera. So that we're offering something that is not only delivering kind of price relative to value, but it's also something very achievable and represents a cost savings for wherever you are. So if you're a small company, you'd be spending 6 figures

02:51in labor on this. We're trying to get under that. If you're a large company, it's a huge expenditure.

Nathan Latka

02:56Give me just because we don't have enough time to earn every cohort, give me the sweet spot. I mean, $50,000 a year? I mean, is that a fair kind sweet spot target for you?

Jared Seehafer

03:04If you were doing a garage startup, that would be exactly it. Yep.

Nathan Latka

03:06Okay. Okay. Fair enough. Good. And then put this on a timeline for us. When did you launch the company? What year?

Company Launch Timeline

Jared Seehafer

03:12So we were in sort of quasi stealth, though I hate the term in 2017, launched the company earlier this year in 2018, Q1.

Nathan Latka

03:21Okay, 2018 launched the company. I mean, get, by the way, why get into this space? This is like, many people would say boring and it's like the government and HIPAA and not fun. I mean, why get into this?

Why Jared Entered the Life Science Regulatory Space

Jared Seehafer

03:31So it's a personal pain for me because I spent my career actually being a biomedical engineer. So my background is in very, very complicated medical devices that treat neurological disorders. The graduate work in doing deep brain stimulation for Parkinson's disease. I tell your listener base, if you ever wanna see a miracle in real life, go YouTube or Google DBS, that's DBS, deep brain stimulation for Parkinson's, and you'll watch something that you do not believe. Someone that's

04:01literally doing tremors, they cannot move, someone flicks a switch and all of a sudden they walk as if they have no problem. So I got into this space really wanting to use technology to transform people's lives and their health. And what I found is being an engineer, that it would take forever to get your products on the market. And it was very expensive and you saw a lot of failures that weren't necessarily related to whether the

04:24product was any good or not or did what you said. And so I'm trying to scratch my own itch. I'm trying to solve problems and create the kind of software that I wish I had had as someone building lifesaving technology.

Nathan Latka

04:38Yep. Yep. Okay. Very good. So kind of stealth last year you launched this year. What have you scaled to today in terms of total customers using the platform?

Customer Count and Platform Scale

Jared Seehafer

04:45So we've got 21 companies that are using the platform in production of various sizes, everything from sort of product teams to the large organizations, enterprise organizations to, like I said, kind of a garage startup.

Nathan Latka

04:55Okay. And 21 paying a $50,000 ACV that puts you right at that nice million dollar run rate. I mean, have you guys passed that at this point?

Jared Seehafer

05:02Yeah, we're right around there.

Nathan Latka

05:03That's great. Congratulations. And a year ago, nothing, right?

Jared Seehafer

05:06A year ago, we were doing essentially very,

05:10you know, small amount kind of early adopter.

Nathan Latka

05:13What are talking like 5

Jared Seehafer

05:13Yeah,

Nathan Latka

05:13grand a

Jared Seehafer

05:16yeah. Well, exactly. You were talking not even like $15.20.

Nathan Latka

05:20Yeah, a 100.

Jared Seehafer

05:21Yeah, 20, Exactly.

Nathan Latka

05:22Yeah. Yeah. Very good. All right. And how did you, I mean, walk me through how you landed the first customer.

Landing the First Customer at a Launch Event

Jared Seehafer

05:28So it was, it was actually quite by a random chance was in, had just kinda started working on the product as a product as a side project for my consulting business and went to on a lark, Jason Kalakanis' launch... One of the launch events in San Francisco here. And I'm just kinda walking around the the little stalls and just looking at interesting biological products and that we found one. And it was one of these things where

06:01I was asking, just asking questions and it would turn out the CEO of the company. He's like, you seem to know a lot about this. What do you do for a living? And I, you know, I mentioned it was starting the company. It's like, it just so happens. We've had this problem. We've been going through consultants. You know, we, you know, we, we hate dealing with them. They're way too expensive, not a whole lot of value.

06:19I'd love a software based solution. Let's go demo the product. And my heart kind of stopped. It was like, oh,

Nathan Latka

06:24this is all right at the launch event.

Jared Seehafer

06:26Yeah. Exactly.

Nathan Latka

06:26That's great.

Jared Seehafer

06:26All basically sort of when the space... Fifteen minutes. It had the demo. The product was a total mess, but it was it was doing enough that they found it valuable, and and we've been working with it ever since.

Nathan Latka

06:39Interesting. Talk to me about how you've capitalized the company. So have you bootstrapped to raise capital?

Capitalization: Y Combinator and Seed Funding

Jared Seehafer

06:44We went through Y Combinator Accelerator, did a small friends and family round, kind of just when I was just getting started. Then went through YC and then raised a seed stage round of capital, you know, through various VCs that are kind of in that, at that cohort right after YC.

Nathan Latka

07:02So all in today, 1,000,000, 2,000,000, something like that?

Jared Seehafer

07:04Couple million. Yeah.

Nathan Latka

07:05Couple million. Okay. Very good. You've... I assume you've done a priced round at this point, right? Or is it all still debt? Convertible.

Jared Seehafer

07:05So

07:11the standard out here these days is just... Is the sort of SAFE type of model. So we've been following that.

Nathan Latka

07:17Okay. So you haven't, you haven't all the, all the couple million has been all on the SAFE. You haven't raised a price round yet.

Jared Seehafer

07:22Right.

Nathan Latka

07:22Okay. Very good. And help me understand kind of what you've scaled team to. How many people?

Team Size and Remote Work Setup

Jared Seehafer

07:27Yeah. So we've got eight people on staff here and we've various kind of mix of developers and sort of regulatory experts.

Nathan Latka

07:35All in San Fran?

Jared Seehafer

07:37Yeah. No. We do a mix of SF and remote. I basically kind of found like a lot of, we found kind of a lot of entrepreneurs out here. It's just that the cost of living situation has sort of made it advantageous to really try to make a quasi remote organization from the ground up.

Nathan Latka

07:51Yeah. Have you been able to dial in yet some of the other economics around, you know, driving customer growth related to like, you know, churn, expansion, revenue, CAC, or is it really too early? Your cohort's too small?

Churn, Retention and the Nature of Regulatory Compliance

Jared Seehafer

08:01Well, so for the nature of our business is such that we don't really see churn. Churn for us is a customer getting bought or acquired. So

Nathan Latka

08:11What about once approved? What if your thing works? What if your thing works and it might think it's approved. Why do I still need you?

Jared Seehafer

08:18Ah, because it's actually, that's a very good question. Most people think of these things as binary and in fact, what we're, you know, or event driven. So my product gets approved. I don't need an FDA person anymore. What most people don't realize about life science regulations is pervasive throughout the life of the company. So think of it a little bit like event driven, but also something like financial regulation or HIPAA, where there are all these rules

08:44around how you manage data and make decisions at a company that are every day for the life of your business, a ton of business process regulation. So what the approval process is, is a summation of this sort of dataset over the last six to twelve or eighteen months, the life of your product development, but it keeps going on. And in addition to the approvals, get audited every couple of years. And you get audited whether you've had

09:07zero new products, one new product, and new products doesn't matter. So the kind of thing for us is it's not, when we kind of take on customers, it's sort of the,

09:18it's almost for the life of the company. Making a big decision in terms of using us to solve this big core problem that you have as an entrepreneur.

Nathan Latka

09:26Got it, got it. You get approval and then there's touch points.

Jared Seehafer

09:29Yep. Yeah. On the flip side of that is that churn for us is like not, it's not a thing that we really have to worry about.

Nathan Latka

09:34Yeah, well, in all fairness too, I mean, you haven't had a history yet where there would even really be a chance for a churn, right? So none yet, sounds like at this point. What about acquisitions? So to get a new $50,000 ACV account, do you know what you're willing to spend to get that?

Growth Drivers and Word-of-Mouth

Jared Seehafer

09:48Not enough data to really understand that. I really understand that yet just because of what we're doing is fairly novel. And so we've got a lot of growth just from word-of-mouth. The cohort of entrepreneurs that's in this space because they vary kind of particular demands tend to know each other. And so there's often kind of question, how are solving this problem? It's a problem everyone has. And so our name has sort of percolated throughout that community

10:12over the course of the past year.

Nathan Latka

10:14Does YC

Jared Seehafer

10:14So I figure I'll have a better answer to that.

10:16Within the future.

Nathan Latka

10:17Yeah. Sorry. Does YC teach you guys to try and drive to cash flow positive before you go out and do a priced round?

Cash Flow and Burn Rate Discussion

Jared Seehafer

10:25Does YC, not really. So what Y, I mean, YC is saying, if you've got that, that's, you know, couldn't... One of the things that can make real an investor ears perk up. But no. Why... I mean, I think YC is, you know, what what what is going to be best for the overall business? If you try to do things that are gonna make you cash flow positive, but then you're gonna fall flat on your face, That's

10:47not very helpful for anybody.

Nathan Latka

10:48Well, of

10:49course, I mean, put it very black and white there, but there's an in between there as to there. I mean, there's an between ground where you can do both, right? You can, you can be profitable and not fall flat on your face. Mean, the reason I ask, the reason I ask is you have eight people and you have a million dollar run rate. I mean, you could actually be profitable cash flow positive right now, even though

11:03you raised $3,000,000. I mean, so the reason I was, what I was gonna ask is like, if you are burning money, where are you burning it? It doesn't look it's headcount.

Jared Seehafer

11:12No, I mean, so where we are going to be burning money is going to be as we sort of drive from you know, transitioning the company to something that's serving these small organizations to larger enterprises is gonna necessitate an enterprise sales force. And so we're kind of about to go on a talent acquisition spree, which is going to drive up burn and then necessitate.

Nathan Latka

11:32Are you cash flow positive today?

Jared Seehafer

11:34Not quite, but close.

Famous Five: Books, Tools and Sleep

Nathan Latka

11:35Really close. Very good. All right, Jared, let's wrap up here with the famous five. Number one, what's your favorite business book?

Jared Seehafer

11:42Oh, what's my favorite? I would say The Essential Drucker. That was something that really informed me. It's basically a collection of all Peter Drucker's most famous management essays.

Nathan Latka

11:53Number two, is there a CEO you're following or studying right now?

Jared Seehafer

11:57Is there a CEO I'm following or studying right now?

12:02I'm studying right now. I would just say I... Because I'm just so inspired by him. It's kind of a tridents, but a lot.

Nathan Latka

12:08Yep.

12:09Number three, what's your favorite online tool for building the company?

Jared Seehafer

12:14We are big Slack fans. I I think Slack's one of these things that gets a bad rap, but I think you tune it very well. It's been essential to us in kinda keeping, you know, keeping a quasi remote org.

Nathan Latka

12:26How many hours of sleep are you getting every night?

Jared Seehafer

12:30Love this question.

Nathan Latka

12:31Listen, I ask because I don't want my audience following a CEO who's doing a 100,000,000 in revenue getting three hours of sleep who's divorced with four kids.

Jared Seehafer

12:41Yeah, I would say on a bad day, it's six on a good day, seven.

Nathan Latka

12:47Okay, that's pretty fair. That's good. And situation married single kids?

Jared Seehafer

12:51I've got a girlfriend.

Nathan Latka

12:52Okay, so not married yet. No kids?

Jared Seehafer

12:55No kids. I don't know how... I have a lot of respect for entrepreneurs who can do seed stage with kids. I have some friends that do it. I don't know how.

Nathan Latka

13:02And how old are you, Jared?

Jared Seehafer

13:03I'm 33.

Nathan Latka

13:0433.

Advice to Younger Self: Start Earlier

Nathan Latka

13:05Last question. What do wish your 20 year old self knew?

Jared Seehafer

13:12Don't be,

13:16I I would say

13:19start earlier. So there was this thing where I had... I've had this idea percolating in my mind for ever since I started my career. And I always was thinking, why isn't anyone doing this? Why isn't anyone doing this? Why isn't anyone doing this? And I got... Eventually I just got fed up enough that I was... I'm gonna go do it. I think I would tick myself a little bit and say, you could probably start three or

13:42four years before you did and have just, you know, that timeline would have been shifted up.

Nathan Latka

13:42Yep. Guys, start earlier.

13:51Guys, I have

13:51from Jared again, start earlier, launched Enzyme back, let's see, just about a year ago and kind of in stealth, 2018 really came to market now about 21 customers paying, call it $50,000 in terms of ACV each. That's about, you know, about a million bucks in run rate today, up from just $1,500 a month a year ago. So healthy growth there, obviously small numbers, but still healthy growth. Hoping to get closer, they're flirting with breakeven right now.

14:11They raised about $3,000,000 all in a SAFE, hoping to do a priced round here soon to grow their enterprise sales force. Currently eight people really tech heavy in San Fran and other remote locations. No churn yet. Too early to talk about CAC and things like payback period, but they are obviously looking to scale. Jared, thank you again so much for taking it. By way, should also put in the summary, again, medical device companies get to market

14:29and get their products to market faster and then also stay compliant. Jared, thank you for taking us to the top.

Jared Seehafer

14:34Yep.